ReNerve LTD

ASX : RNV

2026

ANNUAL REPORT

renerve.com.au

ReNerve LTD

Table of Contents

About ReNerve Limited

ReNerve Limited (ASX:RNV) is transforming nerve repair and improving lives through breakthrough medical technology. Founded by a neurosurgeon and medtech researchers, ReNerve is a rapidly growing medical device company that has revolutionised peripheral nerve surgery with its innovative, ready-to-use solutions for peripheral nerve injuries (PNI). Our scientifically backed products are delivering measurably better outcomes for patients worldwide.

Proven Clinical Success

ReNerve's first flagship product, the FDA-cleared **NervAlign® Nerve Cuff**, is already making a dramatic difference in surgical outcomes across the United States. A recently announced clinical study has demonstrated remarkable results, showing that patients treated with the NervAlign® Nerve Cuff experienced post-surgical pain scores dropping from 7.1 to just 0.4, compared to from 7.1 to 3.3 without the device being used – a statistically significant improvement that's changing lives.

Comparison of Patient Pre & Post Surgery Pain Score



Standard of Care vs NervAlign™ Nerve Cuff Protected Nerve Repairs

The comparison of pain scores between the two cohorts of patients

Comprehensive Product Portfolio

ReNerve is advancing a complete suite of nerve repair solutions and related surgical repairs:

On market

- **NervAlign® Nerve Cuff** – Our bioabsorbable protective wrap, naturally absorbed within six months of surgery.
- **Empliq™ Dermal tissue product --** A unique deep dermal product used in the repair of reconstructive and cosmetic surgical cases.
- **Empliq™ Amniotic tissue product ranges --** Three amniotic tissue product ranges used to aid the healing of wounds.

In development

- **NervAlign® Nerve Conduit Range –** Next-generation nerve conduit leveraging advantages of eCOO technology in a material designed to facilitate nerve growth over short gaps between nerve ends.
- **NervAlign® Nerve Guide Matrix** – a customised and ready-to-use alternative to existing nerve grafts, for treatment of longer nerve gaps and more severe nerve injuries. It will eliminate the need for patients to undergo additional sural nerve harvesting.
- **NervAlign® Bionic Nerve** – Next-generation combination technology for the most challenging nerve repairs.

Market Leadership and Growth

With demonstrated market traction since the Company's 2022 product launch, ReNerve achieved 53% revenue growth in FY25, reaching $271k in sales and YTD FY2026 sales revenues showing further significant increases across its portfolio. Our high-margin, scalable products are positioning us as the go-to solution for surgeons seeking superior patient outcomes in the rapidly expanding global nerve repair market, valued at US$1.6 billion in 2024 and is projected to reach $6.2 billion by 2031.[1]

Vision and Values

We're not just developing medical devices – we're engineering hope. By creating the ideal healing environment for nerve repair and regeneration, ReNerve bridges critical gaps in healthcare while empowering the human body's natural healing process. Our cleaner, safer, and more effective solutions represent the future of peripheral nerve surgery.

[1] Global Nerve Repair Biomaterials Market Research Report (2020 – 2031)

Chair's Letter

Dear Shareholders,

It is a privilege to write to you as Chair of ReNerve Limited following my appointment to the Board and subsequently as Non-Executive Chair. I would like to thank shareholders for their continued support as the Company advances its mission of transforming peripheral nerve repair through innovative medical technologies. My appointment forms part of the Board's renewal process and reflects our commitment to strong governance, strategic discipline and sustainable value creation.

Over the past year, ReNerve has continued to successfully complete major company milestones over the past 12 months, continuing its strategy of expanding the commercial footprint of its FDA-cleared NervAlign® Nerve Cuff while progressing the broader product portfolio and strengthening the foundations required for long-term growth. The Board believes the Company is increasingly well positioned to participate in the significant global opportunity within peripheral nerve repair and regeneration.

A major achievement during the period was the continued expansion of ReNerve's international market access. The Company secured marketing approvals for NervAlign® Nerve Cuff in Hong Kong, Malaysia, Indonesia, the Philippines and India, significantly broadening the potential patient population and creating multiple new commercial pathways across the Asia-Pacific region. These approvals represent important validation of our technology and provide a platform for future revenue growth through local distribution partnerships and surgeon adoption.

ReNerve also continued to strengthen its commercial infrastructure. The establishment of additional distribution arrangements across strategic markets, together with the appointment of J4 as a second manufacturing partner for the Empliq product range, enhances the Company's ability to scale efficiently while maintaining supply chain resilience. These initiatives are important building blocks as we seek to increase market penetration and support future demand.

From a financial and operational perspective, management delivered encouraging progress. For the June 2026 quarter, ReNerve reported record sales of approximately $211,000, and annual sales growth of 88% compared with the prior corresponding period. This outcome demonstrates growing market acceptance of the Company's products and provides further evidence that our commercialisation strategy is gaining momentum.

The Company also took important steps to strengthen its balance sheet and funding flexibility through the execution of a funding facility of up to A$5 million with RiverFort. The facility provides access to growth capital that can support ongoing commercial expansion, product development initiatives and entry into new geographic markets. The Board remains focused on carefully managing capital while ensuring the Company has the resources required to pursue its strategic objectives.

Alongside commercial progress, ReNerve continued to advance its innovation pipeline. During the year, the NervAlign® Nerve Guide Matrix program progressed into Stage 3 of commercial development, representing another important milestone in the Company's strategy to build a comprehensive portfolio addressing the spectrum of peripheral nerve injuries. The Board believes continued investment in differentiated products will be critical to creating long-term shareholder value and improving outcomes for patients globally.

While we are pleased with the progress achieved, we remain focused on the work ahead. Our priorities include accelerating sales growth in existing markets, converting newly approved jurisdictions into meaningful revenue opportunities, further developing our product pipeline and maintaining disciplined capital management. We will also continue to strengthen governance and operational capabilities as ReNerve evolves from an emerging medical technology company into a broader commercial organisation.

The need for innovative and effective nerve repair solutions remains substantial. With a growing international presence, a clinically validated flagship product, an expanding development pipeline and an experienced management team, ReNerve is well positioned to pursue this opportunity.

Looking ahead, our focus is firmly on converting the foundations established to date into sustainable commercial growth and broader market adoption. Over the coming period, we will prioritise accelerating sales of NervAlign® Nerve Cuff in the United States, supporting our distribution partners and converting our expanding international regulatory approvals into new revenue opportunities. At the same time, we will continue to advance the NervAlign® Nerve Conduit and Nerve Guide Matrix through their respective development and clinical pathways, while building the evidence and market presence required to support future adoption. Importantly, we will remain disciplined in how we deploy capital and allocate resources, balancing investment in growth and innovation with the need to build a sustainable and increasingly valuable medical technology company. Our goal is clear: to expand ReNerve's commercial footprint, broaden our product offering and strengthen our position as a leader in peripheral nerve repair.

On behalf of the Board, I would like to thank our shareholders, clinicians, distribution partners, employees and management team for their dedication and support. Their commitment continues to drive ReNerve's progress and brings us closer to our vision of improving the lives of patients suffering from peripheral nerve injuries around the world.

I look forward to updating shareholders on our continued progress in the year ahead.

Yours sincerely,

Maja McGuire

Non-Executive Chair

ReNerve Limited

ReNerve Limited

ABN 23 614 848 216

Annual Report - 30 June 2026

ReNerve Limited
Corporate directory
30 June 2026

Directors	Maja McGuire – Independent Chair & Director Dr Paul Savage – Independent Non-Executive Director Dr Julian Chick – Director & Chief Executive Officer
Company secretary	Mr David Lilja
Notice of annual general meeting	The details of the annual general meeting of ReNerve Limited are: Date: Monday 6th October 2026 Time: 2:00PM (AEDT) Location: To be confirmed
Registered office	DLK Advisory Pty Ltd, Level 10, 99 Queen Street Melbourne, 3000, Australia
Principal place of business	157 Heidelberg Road Northcote VIC 3070, Australia
Auditor	William Buck Level 20, 181 William Street Melbourne VIC 3000, Australia
Solicitors	Cornwalls Level 4, 380 Collins Street Melbourne VIC 3000, Australia
Bankers	ANZ Ground Floor, 55 Collins Street Melbourne VIC 3000, Australia Bendigo Bank The Bendigo Centre Bendigo VIC 3550, Australia
Stock exchange listing	ReNerve Limited shares are listed on the Australian Securities Exchange (ASX code: RNV)
Website	https://renerve.com.au
Corporate Governance Statement	The directors and management are committed to conducting the business of ReNerve Limited in an ethical manner and in accordance with the highest standards of corporate governance. ReNerve Limited has adopted and has substantially complied with the ASX Corporate Governance Principles and Recommendations (Fourth Edition) ('Recommendations') to the extent appropriate to the size and nature of its operations. The company's 2025 Corporate Governance Statement that sets out the corporate governance practices that were in operation during the financial year and identifies and explains any Recommendations that have not been followed, which is approved at the same time as the Annual Report, can be found at: https://renerve.com.au/company-policies/

ReNerve Limited
Directors' report
30 June 2026

The directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'company') consisting of ReNerve Limited (referred to hereafter as the 'company' or 'parent entity') and the entities it controlled at the end of, or during, the year ended 30 June 2026.

Directors
The following persons were directors of the company during the whole of the financial year and up to the date of this report, unless otherwise stated:

Ms Maja McGuire - Independent Chair & Non-Executive Director (Appointed 4 December 2025)
Dr Paul Savage – Independent Non-Executive Director (Appointed 4 December 2025)
Mr Reginald Stephen Cooper – Independent Chair & Non-Executive Director (Ceased 4 December 2025)
Dr Michael Panaccio – Independent Non-Executive Director (Ceased 4 December 2025)
Dr Julian Chick – Director & Chief Executive Officer
Dr David Rhodes – Executive Director & Chief Scientific Officer (Ceased as Director 30 April 2026)

Principal activities
ReNerve has FDA market clearance and is selling its NervAlign® Nerve Cuff product in the US market. During FY2026, the company continued to broaden its commercial activities, with three product lines now being sold in the US and approvals obtained across several Asian markets. ReNerve remains focused on building a portfolio of regenerative biological based tissue products for the repair and replacement of injured peripheral nerves and related surgical procedures.

ReNerve continues to develop its portfolio of medical devices used in the repair and/or replacement of damaged peripheral nerves, with three further product ranges at various stages of development:

a) The NervAlign® Nerve Conduit range
b) The NervAlign® Nerve Guide Matrix
c) The NervAlign® Bionic Replacement Nerve

In addition, ReNerve has expanded its commercial product range through the launch of the Empliq™ human tissue product range, comprising deep dermal and amniotic tissue products. These products are complementary to ReNerve's existing nerve repair products, are sold through the company's existing distribution channels, and are used in the same or related surgical procedures.

Dividends
There were no dividends paid, recommended or declared during the current or previous financial year.

Review of operations
The loss for the company after providing for income tax amounted to $5,572,439 (30 June 2025: $3,733,918).

During FY26, ReNerve progressed from a single-product commercial organisation to a multi-product regenerative medicine company, supported by expanding distribution networks, increasing hospital adoption, new international regulatory approvals and ongoing advancement of its development pipeline. The company believes these achievements position it favourably for continued commercial growth and product portfolio expansion.

The 2026 financial year was a period of significant commercial and operational progress for ReNerve. The company delivered strong sales growth, expanded its portfolio of on-market products, established new commercial channels across the Asia-Pacific region and advanced the development of its next-generation peripheral nerve repair technologies.

Full-year sales increased by 88% to approximately $510k, compared with $271k in FY25. Growth accelerated during the second half, culminating in record quarterly sales of $211,000 in the June quarter, an increase of more than 50% from the previous quarter and the company's largest sales quarter to date.

The growth reflected increasing adoption of the NervAlign® Nerve Cuff, the launch and commercial rollout of the Empliq™ human tissue product range and continued progress in securing new hospital approvals and purchasing approvals. ReNerve also expanded its geographic footprint beyond the United States through regulatory approvals and distribution partnerships in key Asia-Pacific markets.

Alongside its commercial activities, the company continued to invest in the NervAlign® Nerve Conduit and NervAlign® Nerve Guide Matrix development programs. The Nerve Guide Matrix entered Stage 3 of ReNerve's four-stage scaled commercial production process during the year, marking an important step towards formal preclinical testing and a future FDA marketing submission. The company has progressed the initial nerve conduit program to commercial product scale up stage ahead of its launch later in 2026.

ReNerve maintained commercial momentum throughout FY26, with quarterly sales increasing from $66,000 in the September quarter to $97,000 in the December quarter, $135,000 in the March quarter and $211,000 in the June quarter. March 2026 was the first month in which the company recorded sales of more than $100,000.

The stronger performance was driven primarily by growth in the Empliq range and the increasing contribution of multiple products to the company's revenue base. The broader portfolio allows ReNerve to offer hospitals and surgeons a more comprehensive selection of products through the same sales and distribution channels established for the NervAlign Nerve Cuff.

During the year, the company continued to progress new hospital approvals. Three new hospital approvals were secured for the Empliq range during the March quarter, with further applications submitted across six targeted hospital systems. These approvals support adoption across the broader ReNerve portfolio and provide an established pathway for the introduction of future products, subject to regulatory clearance.

The United States remained ReNerve's principal commercial market during FY26. The company continued to build its network of distribution partners, engage surgeons and pursue approvals within individual hospital systems.

A significant milestone was the approval of the NervAlign Nerve Cuff for purchasing through the United States Department of Defense and Department of Veterans Affairs healthcare networks. This provides a simplified purchasing pathway across a network of more than 1,000 military hospitals, clinics, medical centers and outpatient facilities.

ReNerve ended the first half with 21 distribution partners operating across the United States. The combination of distributor coverage, hospital approvals, surgeon engagement and supporting clinical evidence provides a platform from which the company can expand sales of both its existing products and future additions to the NervAlign portfolio.

ReNerve launched the Empliq human tissue product range during FY26, achieving its first sale of the Empliq Deep Dermal product during the September quarter and its first sales of the Empliq amniotic tissue products in October 2025. The range includes a deep dermal product for reconstructive and cosmetic surgical applications and three amniotic tissue product ranges used to support wound healing.

The company introduced the products to surgeons at the American Society for Surgery of the Hand conference in October 2025 and subsequently progressed hospital approvals and commercial adoption through its existing sales channels.

In June 2026, ReNerve appointed J4 Biologics as a second approved manufacturing partner for the Empliq range. J4 is a United States-based human tissue processor specialising in amnion and dermal products. Its appointment followed a qualification and evaluation process covering ReNerve's quality, compliance and production requirements.

The second manufacturing relationship was established in response to growing demand and increasing hospital adoption. It is intended to expand available manufacturing capacity, improve product availability, shorten lead times and reduce supply concentration risk. The arrangement also gives the company greater flexibility to scale Empliq inventory production in line with demand.

ReNerve made significant progress in extending its commercial footprint across the Asia-Pacific region during FY26.

The NervAlign Nerve Cuff received market registration in Malaysia and broader listing approval in Hong Kong, including access to public and private hospitals and hospitals operating within the Greater Bay Area. These approvals complemented ReNerve's existing market access in jurisdictions including the United States, New Zealand and Thailand.

Following the Hong Kong approval, ReNerve entered into an exclusive distribution agreement with Swedish Trading Company covering Hong Kong, Macau and the Greater Bay Area. Swedish Trading Company has established relationships across hospitals and surgical networks in the region and is responsible for importation, warehousing, marketing, sales and distribution. The first stocking orders were shipped into the region during the year.

ReNerve also appointed UG Medical as its commercialisation partner in Malaysia. UG Medical will support importation, regulatory management, warehousing, marketing and distribution of the NervAlign product range through its established Malaysian hospital network. ReNerve will provide clinical and technical support, product training and regulatory liaison as commercial activities progress.

Subsequent to the end of the financial year, the company secured marketing approval for the NervAlign Nerve Cuff in each of India, Indonesia and the Philippines. These are all very significant markets for the growth prospects of ReNerve, with large populations, high road trauma burdens and therefore outstanding market opportunities for the company.

The FDA-cleared NervAlign Nerve Cuff is a bioabsorbable protective wrap designed to provide an environment that supports nerve healing following surgical repair. The product is naturally absorbed within approximately six months of surgery, making it unique in terms of its handling characteristics, its absorption within an ideal time period relative to nerve repair and clean manufacturing process resulting in a clean, safe nerve protective nerve cuff.

During FY26, ReNerve continued its post-market clinical evaluation of the Nerve Cuff, building on statistically significant interim data presented in March 2025. The interim analysis showed that patients treated with the NervAlign Nerve Cuff experienced a reduction in average pain scores from 7.1 before surgery to 0.4 after surgery, compared with a reduction from 7.1 to 3.3 among patients receiving the standard of care without the device. Based on the successful outcomes from this study, ReNerve has initiated a more comprehensive study to illustrate the utility and benefits of the NervAlign Nerve Cuff in the repair of injured nerves.

The clinical evidence continued to support surgeon engagement, hospital purchasing applications and regulatory submissions in new markets.

ReNerve continued to develop its NervAlign Nerve Conduit range during the year. The conduits use the company's proprietary eCOO™ biomaterial technology and are designed to facilitate nerve growth across short gaps between severed nerve ends.

During the early part of FY26, ReNerve finalised the production hardware and manufacturing process for the first products in the conduit range. Development and regulatory work continued during the remainder of the year, with preparations underway for the planned introduction of the product in selected markets, including Malaysia.

The Nerve Conduit is expected to broaden the NervAlign portfolio and allow the company to address nerve injuries that require support across a physical gap, complementing the protective function of the existing Nerve Cuff. The Nerve Conduit has a broader appeal due to the use of nerve conduits globally being a larger segment of the nerve repair market compared to nerve cuffs.

The NervAlign Nerve Guide Matrix is being developed as a ready-to-use solution for the repair or replacement of more severely injured nerves. The product is intended to provide surgeons with an alternative to donor nerve grafts, which can be constrained by limited availability and require patients to undergo an additional nerve-harvesting procedure.

During FY26, ReNerve and its development partner progressed the volume production of prototype Nerve Guide Matrix products. The program subsequently entered Stage 3 of the company's four-stage scaled commercial production process.

Stage 3 represents the manufacturing verification phase and is expected to generate product for formal preclinical testing, associated packaging development and manufacture of the final product configuration. Completion of Stage 3 is targeted for

the end of calendar 2026.

Stage 4 will involve the final production and testing of Nerve Guide Matrix batches ahead of a formal marketing submission. ReNerve continued to engage with the FDA during the development process, with testing activities being designed in consideration of the feedback received.

The program has previously generated positive preclinical results in a nerve regeneration model, supporting the potential of the Nerve Guide Matrix as an alternative for the repair and replacement of injured or damaged nerves.

ReNerve completed a significant Board renewal process during FY26 to strengthen governance, commercial oversight and strategic capability as the company progresses its transition from a development-stage company towards commercialisation. Ms Maja McGuire was appointed as an Independent Non-Executive Director and Interim Chair on 4 December 2025 and subsequently appointed Non-Executive Chair on 19 December 2025. Dr Paul Savage was appointed as an Independent Non-Executive Director on 4 December 2025. Together, the appointments add substantial expertise in governance, medical technology, manufacturing innovation, commercial strategy and ASX-listed company leadership. The Board renewal process coincided with the retirement of Mr Stephen Cooper and Dr Michael Panaccio from the Board.

Dr David Rhodes stepped down as a Director effective 30 April 2026 after nine years of service on the Board. Dr Rhodes remained with ReNerve as Chief Scientific Officer, retaining responsibility for supporting the company's research and development activities and the delivery of its next generation of products.

During the year, ReNerve completed a $3.2 million capital raising. Approximately $2.6 million was received during the December quarter, with the remaining approximately $0.6 million received following shareholder approval and settlement in January 2026.

In February 2026, the company received a Research and Development Tax Incentive refund of $517,133 relating to eligible activities undertaken during the 2025 financial year. The refund recognised ReNerve's continued investment in its proprietary biomaterial and medical device programs.

ReNerve recorded customer cash receipts of $382,739 during FY26. Net cash used in operating activities was approximately $5.80 million, reflecting continued investment in product manufacturing, commercial expansion, staffing and corporate activities.

During the year, the company increased its investment in the Nerve Guide Matrix program, which entered Stage 3 during the June quarter. The company held cash and cash equivalents of approximately $1.49 million at 30 June 2026.

Key risks and uncertainties

The company is subject to risks specific to its business activities, as well as general risks. The major risks and uncertainties are summarised below.

Successful Commercialisation of Assets

The nature of medical device research and development is inherently uncertain at times. There are substantial risks including that clinical studies may fail to achieve acceptable endpoints for efficacy or safety, or the products may not secure acceptance from surgeons and clinicians. Failure in any of these areas would have a material impact on the company's prospects. ReNerve seeks to mitigate risk through a diversified product pipeline, a maturing portfolio of products some of which are on market, continuous engagement with surgeons, careful design of its clinical studies, and collaboration with reputable and experienced partners.

Research and Development Risk

ReNerve's ongoing and future projects require research and development. It is possible that the development of its product portfolio may be more costly or take more time than expected, or may not achieve the expected clinical endpoints. Delays or increased costs could materially impact the company's ability to bring products to market or achieve commercial milestones.

Regulatory and Product Approval Risks

As a medical device company, ReNerve's products are subject to stringent regulatory approval processes in each jurisdiction. The loss, delay or failure to secure required approvals (such as FDA clearance or comparable authorities in other markets) may prevent the commercialisation of its products or expose the company to additional costs and delays. The withdrawal or suspension of existing approvals could significantly affect operations and financial performance. ReNerve monitors regulatory developments and maintains relationships with regulatory consultants and agencies to manage this risk.

Product Acceptance and Commercial Risks
ReNerve relies on acceptance of its products by surgeons. If products are not accepted by surgeons or fail to generate repeat usage, commercial uptake may be limited. The company mitigates this risk through active engagement with opinion leaders, development of clinical data, and education initiatives.

Intellectual Property and Competitive Risk
ReNerve's strategy is to rely on a combination of proprietary know-how, trade secrets, and, to a lesser extent, patents. There is a material risk that competitors could seek to reverse-engineer or copy the company's products, or develop superior alternatives. If ReNerve's trade secrets are not adequately protected, or if key intellectual property is lost or circumvented, it could harm the company's market position. The company proactively manages confidentiality but acknowledges some risks are outside its control.

Manufacturing, Supply Chain, and Dependency on Key Partners
ReNerve's lead products are currently manufactured by a single supplier (EMCM) under an exclusivity agreement that depends on meeting certain obligations. Loss of exclusivity or termination of the supply agreement - whether through default, insolvency, or operational disruption—would require rapid transition to alternative suppliers, which may not be feasible without significant disruption and cost, although ReNerve has identified an alternative manufacturer. Key raw materials (porcine tissue) are sourced from the Netherlands and could be subject to disruption by disease outbreaks or export restrictions although can be sourced from other jurisdictions.

Funding and Liquidity Risk
ReNerve is an early stage company that is currently loss-making and requires substantial additional funding to progress its R&D pipeline and commercial plans. There is a risk that future capital raisings may not be available on acceptable terms, or at all, which could affect the company's ability to continue as a going concern or delay its growth and development objectives.

Market, Economic, and Industry Risk
Broader economic factors and industry dynamics may adversely affect the company. These include changes in healthcare spending, hospital procurement behaviour, reimbursement policy changes, currency fluctuations, and competitive product launches. The company regularly reviews strategy in light of current industry developments.

Reliance on Key Personnel
The success of ReNerve depends in large part on the continued involvement of its executive and scientific management team. The loss of one or more key employees, or inability to attract and retain appropriately qualified personnel as the business grows, may have a material adverse effect on the company's performance.

Reputational and Product Liability Risk
Though none have been experienced, a significant adverse event from the use of ReNerve's products, such as patient injury or product recalls, could result in reputational damage, litigation or regulatory investigations, all of which could materially harm the company's business and financial results.

Activity Levels and Demand Risk
The company's products are sold to hospital and surgeon customers. Any reduction in activity levels - whether due to shifts in surgical practice, economic conditions in the healthcare sector, adverse industry trends, or the emergence of competing products - may reduce demand for ReNerve's products and adversely impact financial performance.

Significant changes in the state of affairs

In July 2025, the company issued 300,000 shares in lieu of cash payment to four Scientific Advisory Board members, as part payment for their services and consultancy activities. In addition, per the sales agent and market development agreement with Emerging Surgical in May 2025, the company issued 473,260 shares on 14 July 2025.

On 24 October 2025, the company granted 870,000 options to employees under the Employee Share Option Plan (ESOP). A further 5,708,526 options, subject to the same terms and conditions, were granted on 2 December 2025. The exercise prices of the options range from $0.20 to $0.60.

In September 2025, the company issued 600,000 shares in lieu of cash payment to Spark Plus, as part payment for their services and consultancy activities.

In December 2025, the company completed a two-tranche share placement at an issue price of $0.12 per share, raising $3.2 million in total, of which $2,589,791 was received during the half-year. The placement was undertaken to support accelerated sales and marketing activities, product launches, and overall growth initiatives.

A total of 21,581,591 shares were issued on 1 December 2025, with the remaining shares to be issued in January 2026 following the reporting date.

On 5 January 2026, the company held a General Meeting where it received shareholder approval for the issue of up to 5,085,080 Tranche 2 placement shares and 26,666,667 one for one free attaching options announced in the November 2025 Capital Raise. Approval was also received for the issue of 4,000,000 Lead Manager options that were announced with the Capital Raise.

Total capital raising costs of $1,107,755 were incurred during the year.

On 12 January 2026, the company announced that its NervAlign® Nerve Cuff has received listing approval in Hong Kong. This approval facilitates extended access to the product for public hospitals as well as the private hospital systems in the Hong Kong region, including facilitating Greater Bay Area hospital access.

On 15 January 2026, the company received market registration (regulatory clearance) in Malaysia for its NervAlign® Nerve Cuff, further expanding its Asia-Pacific regulatory footprint alongside approvals already secured in Hong Kong and Thailand.

On 16 February 2026, the company received a $517,133 R&D Tax Incentive Refund from the Australian Taxation Office, strengthening its cash position for ongoing development activities.

On 18 February 2026, the company issued 746,089 shares in lieu of cash payment to seven Advisory Board members, as part payment for their services and consultancy activities. The shares were issued as consideration with a total value of $89,531.

On 24 March 2026, the company issued 1,010,101 shares in lieu of cash payment for consultancy and advisory services. The shares were issued as consideration with a total value of $100,000.

On 26 June 2026, the company incorporated ReNerve Asia Pte. Ltd., a wholly owned Singapore subsidiary, to support its Asia-Pacific growth strategy.

There were no other significant changes in the state of affairs of the company during the financial year.

Matters subsequent to the end of the financial year

On 9 July 2026, the company announced that it had entered into a funding facility with RiverFort Global Opportunities PCC Ltd for up to $5 million over a three-year availability period. The facility provides the company with access to staged funding to support ongoing commercialisation activities, working capital requirements and general corporate purposes.

An initial drawdown with a face value of approximately $1.6 million was completed under the facility. The drawdown provided approximately $1.361 million in net cash proceeds to the company after the initial issue discount, drawdown fee and legal costs.

The facility is intended to provide additional financial flexibility to support working capital requirements, commercialisation activities, ongoing product development and expansion into new markets. The facility is secured against future eligible R&D Tax Incentive rebates and may be drawn progressively over the three-year availability period.

In August 2026, the company issued 976,301 shares in lieu of cash payment to seven Scientific Advisory Board members, as part payment for their services and consultancy activities.

The company also obtained regulatory approval for the NervAlign® Nerve Cuff in India, Indonesia and the Philippines, expanding its regulatory footprint across the Asia-Pacific region.

No other matter or circumstance has arisen since 30 June 2026 that has significantly affected, or may significantly affect the company's operations, the results of those operations, or the company's state of affairs in future financial years.

Likely developments and expected results of operations
The company's key milestones in the coming 12 to 24 months are expected to be:

- Continued growth in sales of the NervAlign® Nerve Cuff in the USA;
- Continued growth in sales of the Empliq™ tissue product range;
- further hospital approvals and use of the NervAlign® Nerve Cuff across US sales channels, including Department of Defense and Veterans Affairs healthcare systems;
- Further regulatory approvals and commercial partnerships outside the US;
- Continued clinical recruitment and data generation for the NervAlign® Nerve Cuff;
- Launch and commercial progression of the NervAlign® Nerve Conduit;
- Continued progression of the NervAlign® Nerve Guide Matrix program toward clinical trials; and
- Further research and development in relation to the NervAlign® Bionic Replacement Nerve.

The company will continue to aim to grow its commercial business through revenue growth from its NervAlign® Nerve Cuff and Empliq™ product ranges, while also progressing the development and commercialisation of its broader product pipeline to have an extensive portfolio of products available in global markets. ReNerve expects to continue expanding its distribution channels, increasing hospital approvals, supporting surgeon education and pursuing regulatory approvals in additional international markets, resulting in ongoing revenue growth.

Environmental regulation
The company is not subject to any significant environmental regulation under Australian Commonwealth or State law.

Information on directors

Name:	Ms Maja McGuire
Title:	Independent Chair & Non-Executive Director
Qualifications:	BComm, LLB
Experience and expertise:	Ms McGuire brings more than 15 years' experience across board and senior management roles, including as a Non-Executive Chair, Non-Executive Director, General Counsel and Company Secretary of ASX-listed and international companies. She has significant expertise in corporate governance, legal and regulatory matters, mergers and acquisitions, capital raisings, IPOs and strategic corporate transactions. Prior to her board career, Ms McGuire held senior legal and governance positions including General Counsel and Company Secretary at Anteris Technologies and Alexium International Group. She commenced her career in private practice with Clayton Utz and has also held roles with the Canadian Bankers Association.
Other current directorships:	Non-Executive Chair, TechGen Metals Ltd (ASX:TG1) Non-Executive Director, LTR Pharma Ltd (ASX:LTP) Non-Executive Director, Kuniko Ltd (ASX:KNI)
Former directorships (last 3 years):	Non-Executive Director, Indiana Resources Ltd (ASX:IDA)
Interests in shares:	NIL
Interests in options:	NIL

Name:	Dr Paul Savage
Title:	Independent Non-Executive Director
Qualifications:	BSc (Hons), PhD
Experience and expertise:	Dr Savage has more than 35 years' experience in advanced manufacturing, materials science, biotechnology and commercialisation. Prior to retiring in February 2025, he served as Science and Deputy Director of CSIRO's Manufacturing Research Unit, where he was responsible for leading multidisciplinary research programs and applying innovative technologies to industrial and healthcare challenges. Dr Savage has extensive experience in bringing new technologies from research through commercial development and has worked closely with industry, government and research organisations throughout his career
Other current directorships:	
Former directorships (last 3 years):	
Interests in shares:	NIL
Interests in options:	NIL

Name:	Dr Julian Chick
Title:	Director & Chief Executive Officer
Qualifications:	BSc, PhD
Experience and expertise:	Julian is an experienced healthcare executive with over 27 years of experience in senior management and board positions including in ASX listed companies Avexa and Admedus. His roles have included Chief Executive Officer, COO, Head of Business Development, as well as running early and late-stage R&D projects. Julian has launched medical devices into the global markets. Julian while COO at Admedus Ltd was involved in the R&D development, regulatory approval, and launch of several tissue products in North America, Europe, and Asia. He has 10 years of investment banking experience and has also held a role as an analyst reviewing healthcare and biotechnology investment opportunities for private equity investors and venture capitalists. Julian has a PhD in Muscle Physiology.
Other current directorships:	LTR Pharma (ASX:LTP)
Former directorships (last 3 years):	Cann Group (ASX:CAN)
Interests in shares:	14,839,868 ordinary shares
Interests in options:	3,493,603 unlisted options

Other current directorships' quoted above are current directorships for listed entities only and excludes directorships of all other types of entities, unless otherwise stated.

Former directorships (last three years) quoted above are directorships held in the last three years for listed entities only and excludes directorships of all other types of entities, unless otherwise stated.

Company secretary
David Lilja (Appointed 27 August 2020)

David Lilja (B.Bus, MBA, CTA, MIPA) is a qualified accountant and experienced company secretary with over 22 years' experience within the professional services industry working across a wide range of industries. David supplies his services through his firm, DLK Advisory, which provides a breadth of support to its clients including outsourced CFO and Company Secretary services.

Meetings of directors
The number of meetings of the company's Board of Directors ('the Board') held during the year ended 30 June 2026, and the number of meetings attended by each director, were:

	Full Board		Audit & Risk Committee		Remuneration & Nomination Committee	
	Attended	Held	Attended	Held	Attended	Held
Reginald Stephen Cooper	5	5	1	1	1	1
Michael Panaccio	5	5	1	1	1	1
Julian Chick	12	12	2	2	2	2
David Rhodes	10	10	-	-	-	-
Maja McGuire	7	7	1	1	1	1
Paul Savage	7	7	1	1	1	1

Held: represents the number of meetings held during the time the director held office or was a member of the relevant committee.

During the year ended 30 June 2026, the Board held 12 meetings. The Audit & Risk Committee and Remuneration & Nomination Committee each held 2 meetings.

Remuneration report (Audited)
The remuneration report details the key management personnel remuneration arrangements for the company, in accordance with the requirements of the Corporations Act 2001 and its Regulations.

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including all directors.

The remuneration report is set out under the following main headings:
- Details of remuneration
- Service agreements
- Share-based compensation
- Additional disclosures relating to key management personnel

Principles used to determine the nature and amount of remuneration
The objective of the company's executive reward framework is to ensure reward for performance is competitive and appropriate for the results delivered. The framework aligns executive reward with the achievement of strategic objectives and the creation of value for shareholders, and it is considered to conform to the market best practice for the delivery of reward. The Board of Directors ('the Board') ensures that executive reward satisfies the following key criteria for good reward governance practices:
- Competitiveness and reasonableness
- Acceptability to shareholders
- Performance linkage / alignment of executive compensation
- Transparency
- Capital management

The company has structured an executive remuneration framework that is market competitive and complementary to the reward strategy of the organisation. It aims to align shareholders' and program participants' interests:
- Focuses on sustained growth in shareholder wealth
- Attracts and retains high calibre executives
- Rewards capability and experience
- Provides a clear structure for earning rewards

In accordance with best practice corporate governance, the structure of non-executive director and executive director remuneration is separate.

Non-executive directors remuneration
Fees and payments to non-executive directors reflect the demands and responsibilities of their role. Non-executive directors' fees and payments are reviewed annually by the Board. The Board may, from time to time, receive advice from independent remuneration consultants to ensure non-executive directors' fees and payments are appropriate and in line with the market.

ASX listing rules require the aggregate non-executive directors' remuneration be determined periodically by a general meeting. The most recent determination was at the Annual General Meeting held on 7 November 2024, where the shareholders approved a maximum annual aggregate remuneration of $300,000.

Executive directors remuneration
The company aims to reward executives based on their position and responsibility, with a level and mix of remuneration which has both fixed and variable components.

The executive remuneration and reward framework has four components:
- base pay and non-monetary benefits
- short-term performance incentives, payable either in cash or via equity-related instruments
- long-term performance incentives, payable in equity-related instruments
- other remuneration such as superannuation and long service leave

The combination of these constitutes the executive's total remuneration.

Executives may receive their fixed remuneration in the form of cash or other fringe benefits where it does not create any additional costs to the company and provides additional value to the executive.

The short-term incentives ('STI') program is designed to align the targets of the company with the performance hurdles of executives. STI payments are granted to executives based on the achievement of specific annual targets and key performance indicators ('KPIs'). Any bonuses payable may be settled in cash, shares, options or other equity securities, at the election of the Board.

The long-term incentives ('LTI') include the issue of options under the company's Employee Option Scheme. Options will vest to executives based on achievement of long-term incentive measures. These include share price and other performance criteria, subject to continued employment of the Employee by the company, on terms as determined by the Board.

The Nomination and Remuneration Committee reviewed the long-term equity-linked performance incentives specifically for executives during the year ended 30 June 2026.

Details of remuneration

Amounts of remuneration
Details of the remuneration of key management personnel of the company are set out in the following tables.

The key management personnel of the company consisted of the following directors and other personnel of the company:
- Maja McGuire - Independent Chair & Non-Executive Director (Appointed 4 December 2025)
- Paul Savage - Independent Non-Executive Director (Appointed 4 December 2025)
- Reginald Stephen Cooper – Independent Chair & Non-Executive Director (Ceased 4 December 2025)
- Michael Panaccio – Independent Non-Executive Director (Ceased 4 December 2025)
- Julian Chick – Director & CEO
- David Rhodes – Director & CSO (Ceased as Director 30 April 2026)

	Short-term benefits		Post-employment benefits	Long-term benefits and	Share-based payments	
2026	Cash salary and fees $	Cash bonus $	Super-annuation $	Long service leave $	Equity-settled options $	Total $
Non-Executive Directors:						
Maja McGuire	36,750	-	-	-	-	36,750
Paul Savage	12,655	-	1,519	-	-	14,174
Reginald Stephen Cooper	38,315	-	4,597	-	-	42,912
Michael Panaccio	18,496	-	-	-	-	18,496
Executive Directors:						
Julian Chick	372,642	15,000	34,158	6,235	156,970	585,005
David Rhodes	259,032	-	31,084	4,333	87,661	382,110
	737,890	15,000	71,358	10,568	244,631	1,079,447

Other Transactions with Key Management Personnel
At 30 June 2026, a receivable of $12,539 was owing from the Chief Executive Officer relating to superannuation contributions paid in excess of contractual entitlements. Refer to note 30 for further details.

	Short-term benefits		Post-employment benefits	Long-term benefits and	Share-based payments	
2025	Cash salary and fees $	Cash bonus $	Super-annuation $	Long service leave $	Equity-settled options $	Total $
Non-Executive Directors:						
Reginald Stephen Cooper	37,541	-	-	-	-	37,541
Michael Panaccio	25,623	-	-	-	-	25,623
Executive Directors:						
Julian Chick	313,072	-	36,425	5,279	-	354,776
David Rhodes	251,344	10,000	29,106	4,335	-	294,785
	627,580	10,000	65,531	9,614	-	712,725

Service agreements
Remuneration and other terms of employment for key management personnel are formalised in service agreements. Details of these agreements are as follows:

Name:	Dr Julian Chick
Title:	Director & Chief Executive Officer
Agreement commenced:	11 October 2024
Terms of agreement:	(a) Remuneration: Fixed annual salary $435,000 (inclusive of director's fees) including statutory employer superannuation contribution; (b) Short-term incentives: Eligible for an additional payment to the value of 20% of base remuneration, based on successful achievement of Board approved short-term incentive targets; (c) Long-term incentives: Eligible for an annual issue of options to the value of 20% of base remuneration, based on successful achievement of Board approved long-term incentive targets; (d) Termination: The company and Dr Chick may terminate the Executive Services Agreement without cause giving the other party six months' notice.
Name:	Dr David Rhodes
Title:	Chief Scientific Officer & Executive Director
Agreement commenced:	15 October 2024
Terms of agreement:	(a) Remuneration: Fixed annual salary $360,000 (inclusive of director's fees) including statutory employer superannuation contribution; (b) Short-term incentives: Eligible for an additional payment to the value of 20% of base remuneration, based on successful achievement of Board approved short-term incentive targets; (c) Long-term incentives: Eligible for an annual issue of options to the value of 20% of base remuneration, based on successful achievement of Board approved long-term incentive targets; (d) Termination: The company and Dr Rhodes may terminate the Executive Services Agreement without cause, with the company providing Dr Rhodes six months' notice, or Dr Rhodes providing the company with three months' notice.

As at 30 June 2026, no other key management personnel have any service agreement with the entity.

The proportion of remuneration linked to performance and the fixed proportion are as follows:

	Fixed remuneration		At risk - STI		At risk - LTI	
Name	2026	2025	2026	2025	2026	2025
Non-Executive Directors:						
Maja McGuire	100%	-	-	-	-	-
Paul Savage	100%	-	-	-	-	-
Reginald Stephen Cooper	100%	100%	-	-	-	-
Michael Panaccio	100%	100%	-	-	-	-
Executive Directors:						
Julian Chick	71%	100%	25%	-	4%	-
David Rhodes	77%	100%	17%	-	6%	-

The at-risk remuneration percentages for the year ended 30 June 2026 include the fair value of STI and LTI options granted during the year relating to performance outcomes for both the years ended 30 June 2025 and 30 June 2026. Accordingly, the disclosed percentages may not be directly comparable to the annual incentive opportunities specified in the executive service agreements.

Share-based compensation

Issue of shares
There were no shares issued to directors and other key management personnel as part of compensation during the year ended 30 June 2026.

Options
The terms and conditions of each grant of options over ordinary shares affecting remuneration of directors and other key management personnel in this financial year or future reporting years are as follows:

Name	Number of options granted	Grant date	Vesting date and exercisable date	Expiry date	Exercise price	Fair value per option at grant date
Julian Chick	1,072,496	02/12/2025	02/12/2025	02/12/2030	$0.20	$0.053
Julian Chick	355,631	02/12/2025	02/12/2025	02/12/2030	$0.25	$0.048
Julian Chick	1,293,120	02/12/2025	02/12/2025	02/12/2030	$0.30	$0.044
Julian Chick	350,162	02/12/2025	02/12/2025	02/12/2030	$0.40	$0.037
Julian Chick	422,194	02/12/2025	02/12/2025	02/12/2030	$0.60	$0.029
David Rhodes	540,583	02/12/2025	02/12/2025	02/12/2030	$0.20	$0.053
David Rhodes	182,601	02/12/2025	02/12/2025	02/12/2030	$0.25	$0.048
David Rhodes	651,787	02/12/2025	02/12/2025	02/12/2030	$0.30	$0.044
David Rhodes	290,134	02/12/2025	02/12/2025	02/12/2030	$0.40	$0.037
David Rhodes	349,818	02/12/2025	02/12/2025	02/12/2030	$0.60	$0.029

Options granted carry no dividend or voting rights.

Additional disclosures relating to key management personnel

Shareholding
The number of shares in the company held during the financial year by each director and other members of key management personnel of the company, including their personally related parties, is set out below:

	Balance at the start of the year	Received as part of remuneration	Additions	Disposals / other	Balance at the end of the year
Ordinary shares					
Reginald Stephen Cooper	10,643,434	-	100,000	-	10,743,434
Michael Panaccio	3,662,250	-	-	-	3,662,250
Julian Chick	14,539,868	-	300,000	-	14,839,868
David Rhodes	11,527,500	-	-	-	11,527,500
Maja McGuire	-	-	-	-	-
Paul Savage	-	-	-	-	-
	40,373,052	-	400,000	-	40,773,052

Stephen Cooper and Michael Panaccio ceased to be Key Management Personnel during the financial year and are included in the above table as they were Key Management Personnel for part of the reporting period.

During the financial year ended 30 June 2026, the entity did not employ or use the services of remuneration consultants.

Option holding
The number of options over ordinary shares in the company held during the financial year by each director and other members of key management personnel of the company, including their personally related parties, is set out below:

	Balance at the start of the year	Granted	Exercised	Expired/ forfeited/ other	Balance at the end of the year
Options over ordinary shares					
Julian Chick	-	3,493,603	-	-	3,493,603
David Rhodes	-	2,014,923	-	-	2,014,923
	-	5,508,526	-	-	5,508,526

This concludes the remuneration report, which has been audited.

Shares issued on the exercise of options
There were no ordinary shares of ReNerve Limited issued on the exercise of options during the year ended 30 June 2026 and up to the date of this report.

Shares under option
Unissued ordinary shares of ReNerve Limited under option at the date of this report are as follows:

Grant date	Expiry date	Exercise price	Number under option
17/04/2023	17/04/2028	$0.25	60,000
17/04/2023	17/04/2028	$0.25	40,000
01/07/2024	01/07/2029	$0.35	50,000
01/07/2024	01/07/2029	$0.35	50,000
01/07/2024	01/07/2029	$0.35	50,000
11/09/2024	11/09/2029	$0.35	200,000
11/09/2024	11/09/2029	$0.35	200,000
11/09/2024	11/09/2029	$0.35	200,000
22/11/2024	22/11/2027	$0.30	2,951,595
30/04/2025	01/02/2030	$0.12	33,334
30/04/2025	01/02/2030	$0.15	33,333
30/04/2025	01/02/2030	$0.20	33,334
30/04/2025	01/02/2030	$0.30	33,333
24/10/2025	24/10/2030	$0.20	123,334
24/10/2025	24/10/2030	$0.25	148,333
24/10/2025	24/10/2030	$0.30	248,333
02/12/2025	02/12/2030	$0.20	1,613,079
02/12/2025	02/12/2030	$0.25	538,232
02/12/2025	02/12/2030	$0.30	1,944,907
02/12/2025	02/12/2030	$0.40	640,296
02/12/2025	02/12/2030	$0.60	772,012
15/01/2026	15/01/2028	$0.18	26,666,667
15/01/2026	15/01/2029	$0.24	4,000,000
			40,630,122

During the year ended 30 June 2026, the company granted a total of 37,245,193 new options. A total of 500,000 previously issued options expired during the year, and a further 716,666 options lapsed during the year.

Proceedings on behalf of the company
No person has applied to the Court under section 237 of the Corporations Act 2001 for leave to bring proceedings on behalf of the company, or to intervene in any proceedings to which the company is a party for the purpose of taking responsibility on behalf of the company for all or part of those proceedings.

Indemnification of Directors
The company has indemnified the directors and executives of the company for costs incurred, in their capacity as a director or executive, for which they may be held personally liable, except where there is a lack of good faith.

During the financial year, the company paid a premium in respect of a contract to insure the directors and executives of the company against a liability to the extent permitted by the Corporations Act 2001. The contract of insurance prohibits disclosure of the nature of the liability and the amount of the premium.

Auditor
William Buck continues in office in accordance with section 327 of the Corporations Act 2001.

There are no officers of the company who are former partners of William Buck.

No non-audit services were provided during the financial year by the auditor.

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this directors' report.

ReNerve Limited
Directors' report
30 June 2026

This report is made in accordance with a resolution of directors, pursuant to section 298(2)(a) of the Corporations Act 2001.

On behalf of the directors

Maja McGuire
Independent Chair & Non-Executive Director

28 August 2026

William Buck
ACCOUNTANTS & ADVISORS

Lead Auditor's Independence Declaration under Section 307C of the Corporations Act 2001

To the directors of ReNerve Limited

As lead auditor for the audit of ReNerve Limited for the year ended 30 June 2026, I declare that, to the best of my knowledge and belief, there have been:

- no contraventions of the auditor independence requirements as set out in the *Corporations Act 2001* in relation to the audit; and
- no contraventions of any applicable code of professional conduct in relation to the audit.

William Buck Audit (Vic) Pty Ltd
ABN 59 116 151 136

J. C. Luckins
Director
Melbourne, 28 August 2026

ReNerve Limited
Contents
30 June 2026

General information

The financial statements cover ReNerve Limited as a consolidated entity consisting of ReNerve Limited and the entities it controlled at the end of, or during, the year. The financial statements are presented in Australian dollars, which is ReNerve Limited's functional and presentation currency.

ReNerve Limited is a public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business are:

Registered office	**Principal place of business**
DLK Advisory Pty Ltd, Level 10, 99 Queen Street Melbourne, 3000, Australia	157 Heidelberg Road Northcote VIC 3070, Australia

A description of the nature of the company's operations and its principal activities is included in the directors' report, which is not part of the financial statements.

The financial statements were authorised for issue, in accordance with a resolution of directors, on 28 August 2026. The directors have the power to amend and reissue the financial statements.

ReNerve Limited
Statement of profit or loss and other comprehensive income
For the year ended 30 June 2026

	Note	2026 $	2025 $
Revenue			
Revenue	4	510,357	271,707
Cost of sales		(239,033)	(27,041)
Gross profit		271,324	244,666
Other income	5	954,975	969,445
Expenses			
Employment		(1,845,700)	(1,071,946)
Share based payments		(298,775)	(555,079)
Research and development		(1,359,500)	(1,000,757)
Corporate Expenditure	6	(3,294,763)	(2,320,247)
Loss before income tax expense		(5,572,439)	(3,733,918)
Income tax expense	7	-	-
Loss after income tax expense for the year attributable to the owners of ReNerve Limited		(5,572,439)	(3,733,918)
Other comprehensive income for the year, net of tax		-	-
Total comprehensive loss for the year attributable to the owners of ReNerve Limited		(5,572,439)	(3,733,918)
		Cents	**Cents**
Basic earnings per share	31	(3.50)	(3.03)
Diluted earnings per share	31	(3.50)	(3.03)

The above statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

ReNerve Limited
Statement of financial position
As at 30 June 2026

	Note	2026 $	2025 $
Assets			
Current assets			
Cash and cash equivalents		1,488,056	4,754,229
Trade and other receivables	8	1,645,426	790,119
Inventories	9	71,893	199,718
Prepayments	10	632,651	188,317
Monies held in trust	11	327,517	137,099
Total current assets		4,165,543	6,069,482
Non-current assets			
Plant and equipment	12	113,964	59,813
Right-of-use assets	13	115,470	-
Intangibles	14	83,470	20,713
Other deposits		55,715	44,165
Total non-current assets		368,619	124,691
Total assets		4,534,162	6,194,173
Liabilities			
Current liabilities			
Trade and other payables	15	285,218	435,003
Accrued expenses		173,855	108,481
Employee benefits	18	325,008	275,108
Borrowings	16	84,328	-
Lease liabilities	17	100,081	-
Provisions	19	364,166	143,467
Total current liabilities		1,332,656	962,059
Non-current liabilities			
Lease liabilities	17	17,145	-
Employee benefits	18	8,115	36,812
Total non-current liabilities		25,260	36,812
Total liabilities		1,357,916	998,871
Net assets		3,176,246	5,195,302
Equity			
Issued capital	20	19,384,123	17,022,293
Reserves	21	1,505,084	362,730
Accumulated losses		(17,712,961)	(12,189,721)
Total equity		3,176,246	5,195,302

The above statement of financial position should be read in conjunction with the accompanying notes

ReNerve Limited
Statement of changes in equity
For the year ended 30 June 2026

	Issued capital $	Reserves $	Accumulated losses $	Total equity $
Balance at 1 July 2024	8,076,928	202,703	(8,455,803)	(176,172)
Loss after income tax expense for the year	-	-	(3,733,918)	(3,733,918)
Other comprehensive income for the year, net of tax	-	-	-	-
Total comprehensive loss for the year	-	-	(3,733,918)	(3,733,918)
Transactions with owners in their capacity as owners:				
Contributions of equity, net of transaction costs (note 20)	8,806,588	-	-	8,806,588
Share-based payments (note 28)	-	298,804	-	298,804
Expiry of advisor options	138,777	(138,777)	-	-
Balance at 30 June 2025	17,022,293	362,730	(12,189,721)	5,195,302

	Issued capital $	Reserves $	Accumulated losses $	Total equity $
Balance at 1 July 2025	17,022,293	362,730	(12,189,721)	5,195,302
Loss after income tax expense for the year	-	-	(5,572,439)	(5,572,439)
Other comprehensive income for the year, net of tax	-	-	-	-
Total comprehensive loss for the year	-	-	(5,572,439)	(5,572,439)
Transactions with owners in their capacity as owners:				
Contributions of equity, net of transaction costs (note 20)	2,361,830	-	-	2,361,830
Share-based payments (note 28)	-	1,191,553	-	1,191,553
Expiry of options	-	(49,199)	49,199	-
Balance at 30 June 2026	19,384,123	1,505,084	(17,712,961)	3,176,246

The above statement of changes in equity should be read in conjunction with the accompanying notes

ReNerve Limited
Statement of cash flows
For the year ended 30 June 2026

	Note	2026 $	2025 $
Cash flows from operating activities			
Cash receipts from customers		382,739	278,719
Payments to suppliers and employees		(6,806,546)	(3,893,674)
Interest received		106,611	114,402
Receipts from research and development grant credits		517,133	516,606
Net cash used in operating activities	29	(5,800,063)	(2,983,947)
Cash flows from investing activities			
Payments for plant and equipment	12	(73,671)	(48,428)
Payments for intangibles	14	(73,710)	(16,873)
Net cash used in investing activities		(147,381)	(65,301)
Cash flows from financing activities			
Proceeds from issue of shares	20	3,200,000	7,000,000
Payments from the issue of convertible notes		-	755,000
Transaction costs related to issues of equity securities or convertible debt securities		(277,977)	(653,646)
Repayment of borrowings		(80,501)	-
Repayment of lease liabilities		(77,989)	(14,475)
Net cash from financing activities		2,763,533	7,086,879
(Decrease)/increase in cash and cash equivalents		(3,183,911)	4,037,631
Cash and cash equivalents at the beginning of the financial year		4,754,229	711,909
Effects of exchange rate changes on cash and cash equivalents		(82,262)	4,689
Cash and cash equivalents at the end of the financial year		1,488,056	4,754,229

The above statement of cash flows should be read in conjunction with the accompanying notes

Note 1. Material accounting policy information

The accounting policies that are material to the company are set out below. The accounting policies adopted are consistent with those of the previous financial year, unless otherwise stated.

New or amended Accounting Standards and Interpretations adopted
The company has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the company.

The following Accounting Standards and Interpretations are most relevant to the company:

Basis of preparation
These general purpose financial statements have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') and the Corporations Act 2001, as appropriate for for-profit oriented entities. These financial statements also comply with International Financial Reporting Standards as issued by the International Accounting Standards Board ('IASB').

Historical cost convention
The financial statements have been prepared under the historical cost convention modified by the revaluation of select financial liabilities.

Comparative figures
Where required by Accounting Standards, comparative figures have been adjusted to conform to changes in presentation for the current period.

Critical accounting estimates
The preparation of the financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the company's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, are disclosed in note 2.

Parent entity information
In accordance with the Corporations Act 2001, these financial statements present the results of the company only. Supplementary information about the parent entity is disclosed in note 26.

Principles of consolidation
The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of ReNerve Limited ('company' or 'parent entity') as at 30 June 2026 and the results of all subsidiaries for the year then ended. ReNerve Limited and its subsidiaries together are referred to in these financial statements as the 'company'.

Subsidiaries are all those entities over which the company has control. The company controls an entity when the company is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the company. They are de-consolidated from the date that control ceases.

Intercompany transactions, balances and unrealised gains on transactions between entities in the company are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the company.

Operating segments
Operating segments are presented using the 'management approach', where the information presented is on the same basis as the internal reports provided to the Chief Operating Decision Makers ('CODM'). The CODM is responsible for the allocation of resources to operating segments and assessing their performance.

Note 1. Material accounting policy information (continued)

Revenue recognition
The company recognises revenue as follows:

Revenue from contracts with customers
Revenue is recognised at an amount that reflects the consideration to which the company is expected to be entitled in exchange for transferring goods to a customer. For each contract with a customer, the company identifies the contract with a customer; identifies the performance obligations in the contract; determines the transaction price which takes into account estimates of variable consideration and the time value of money; allocates the transaction price to the separate performance obligations on the basis of the relative stand-alone selling price of each distinct good to be delivered; and recognises revenue when or as each performance obligation is satisfied in a manner that depicts the transfer to the customer of the goods promised.

Sale of goods
Revenue from the sale of goods is recognised at the point in time when the customer obtains control of the goods, which is generally at the time of delivery. The transaction price is determined based on the agreed consideration, adjusted for any variable consideration, such as discounts, rebates, or refunds, if applicable. Any estimates of such variable consideration are made using the expected value or most likely amount method and are constrained where necessary to prevent significant revenue reversals.

Government grants
Government grants are recognised in the profit or loss on a systematic basis over the periods in which ReNerve recognises, as expenses, the related costs for which the grants are intended to compensate.

R&D tax offset receivable
For financial reporting purposes, the R&D tax offset is analogised as other income see note 5. A credit will be recognised within other income when there is reasonable assurance that R&D tax offset will be received and conditions will be complied with.

Borrowings
Loans and borrowings are initially recognised at the fair value of the consideration received, net of transaction costs. They are subsequently measured at amortised cost using the effective interest method.

Finance costs
Finance costs attributable to qualifying assets are capitalised as part of the asset. All other finance costs are expensed in the period in which they are incurred.

Issued capital
Ordinary shares are classified as equity.

Earnings per share

Basic earnings per share
Basic earnings per share is calculated by dividing the profit attributable to the owners of ReNerve Limited, excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the financial year.

Diluted earnings per share
Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares.

New Accounting Standards and Interpretations not yet mandatory or early adopted
Australian Accounting Standards and Interpretations that have recently been issued or amended but are not yet mandatory, have not been early adopted by the company for the annual reporting period ended 30 June 2026. The company's assessment of the impact of these new or amended Accounting Standards and Interpretations, most relevant to the company, are set out below.

Note 1. Material accounting policy information (continued)

AASB 18 Presentation and Disclosure in Financial Statements
This standard is applicable to annual reporting periods beginning on or after 1 January 2027 and early adoption is permitted. The standard replaces IAS 1 'Presentation of Financial Statements', with many of the original disclosure requirements retained and there will be no impact on the recognition and measurement of items in the financial statements. But the standard will affect presentation and disclosure in the financial statements, including introducing five categories in the statement of profit or loss and other comprehensive income: operating, investing, financing, income taxes and discontinued operations. The standard introduces two mandatory sub-totals in the statement: 'Operating profit' and 'Profit before financing and income taxes'. There are also new disclosure requirements for 'management-defined performance measures', such as earnings before interest, taxes, depreciation and amortisation ('EBITDA') or 'adjusted profit'. The standard provides enhanced guidance on grouping of information (aggregation and disaggregation), including whether to present this information in the primary financial statements or in the notes. The company will adopt this standard from 1 July 2027 and it is expected that there will be a significant change to the layout of the statement of profit or loss and other comprehensive income.

Note 2. Critical accounting judgements, estimates and assumptions

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements, estimates and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgements and estimates will seldom equal the related actual results. The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities (refer to the respective notes) within the next financial year are discussed below.

Critical Accounting Estimates

Share-based payment transactions
The company measures the cost of equity-settled transactions by reference to the fair value of the equity instruments at the date at which they are granted. The fair value is determined by using the Black-Scholes model taking into account the terms and conditions upon which the instruments were granted (see note 28). The accounting estimates and assumptions relating to equity-settled share-based payments would have no impact on the carrying amounts of assets and liabilities within the next annual reporting period but may impact profit or loss and equity.

Going concern
The directors have assessed the company's ability to continue as a going concern, taking into consideration cash flow forecasts, expected funding sources and anticipated operating expenditure. Based on this assessment, the directors consider it appropriate to prepare the financial statements on a going concern basis.

Non-recognition of carry forward tax losses
The balance of future income tax benefit arising from the current financial year tax losses and timing differences have not been recognised as an asset because it is not clear when the losses will be recovered. The cumulative future income tax benefit estimated has not been recognised as an asset and will only be obtained if:

- the company derives future assessable income of a nature and an amount sufficient to enable the benefit to be realised;
- the company continues to comply with the conditions for deductibility imposed by law; and
- no changes in tax legislation adversely affecting the company realising the benefit.

Critical Accounting Judgements

Lodgement of R&D claims
Over the past 5 years, the entity has successfully claimed for and received cash from the Australian Taxation Office in-respect of credits for its research and development program. Under this program, the ATO has the right, extending back 4 tax years to investigate, audit and potentially clawback these claims in the event that they fail to meet the necessary criteria as established under the research and development credit claim legislation and regulations. It is the directors' view that there is no probable likelihood that any potential action may take place based upon the following reasons:

Note 2. Critical accounting judgements, estimates and assumptions (continued)

- Upon submission of the claim, the ATO and AusIndustry conduct an overall desktop review of the claim, including the eligibility of any overseas research and development activity undertaken (which requires an Advanced Overseas Finding before being eligible);
- The industry environment in which the entity deals is known for its research and development activities which have historically been supported through research and development claims; and
- The entity has a track record extending 5 years of never being challenged on its research and development claims by the ATO or AusIndustry.

During the year, the company finalised its R&D tax incentive claim relating to the year ended 30 June 2025. The final amount received was $517,133 compared to the previously recognised estimate of $685,691, resulting in a $168,557 adjustment recognised in the current year, due to finalisation of eligible expenditure and assessment adjustments.

Note 3. Operating segments

Management has determined the operating segments based on the reports reviewed by the Board of Directors. During the year, the company continued to operate in one segment, being Medical Devices for damaged peripheral nerves.

Major customers
During the reporting period, sales to two individual customers each exceeded 10% of total revenue, representing approximately 18% and 12%, respectively. These customers are located in the United States.

Geographical information

	Sales to external customers	
	2026	**2025**
	$	**$**
New Zealand	2,311	738
United States	508,046	267,873
Hong Kong	-	3,096
	510,357	271,707

Note 4. Revenue

	2026	**2025**
	$	**$**
Sale of goods	510,357	271,707

Disaggregation of revenue
The disaggregation of revenue from contracts with customers is as follows:

	2026	**2025**
	$	**$**
Timing of revenue recognition		
Goods transferred at a point in time	510,357	271,707

Note 5. Other income

	2026 $	2025 $
Interest received	89,905	144,216
R&D credits	865,070	825,229
	954,975	969,445

Note 6. Corporate Expenditure

	2026 $	2025 $
Administration expenses	1,114,450	606,407
Marketing and selling costs	1,198,354	646,687
Depreciation and amortisation expense	110,218	46,117
Finance costs	11,109	249,456
Professional fees	639,933	628,113
Manufacturing provision expense	220,699	143,467
	3,294,763	2,320,247

Note 7. Income tax benefit

Unrecognised deferred tax assets

As at 30 June 2026, the company has unutilised tax losses of $11,173,815 (2025: $7,057,819) for which no deferred tax asset has been recognised due to the uncertainty regarding future taxable profits.

Note 8. Trade and other receivables

	2026 $	2025 $
Trade receivables	178,479	39,657
Less: Allowance for expected credit losses	(20,240)	(9,531)
	158,239	30,126
Other receivables	414,540	6,806
GST receivable	37,021	37,682
Interest receivable	1,999	29,814
Research & Development refund receivable	1,033,627	685,691
	1,645,426	790,119

During the year, the company finalised its R&D tax incentive claim relating to the year ended 30 June 2025. The final amount received was $517,133 compared to the previously recognised estimate of $685,691, resulting in a $168,557 adjustment recognised in the current year, due to finalisation of eligible expenditure and assessment adjustments.

Other receivables at 30 June 2026 primarily comprise amounts recoverable from a supplier in respect of inventory prepayments. These amounts were refunded subsequent to year end.

Allowance for expected credit losses
The company has recognised a loss of $10,709 (2025: gain of $631) in profit or loss in respect of the expected credit losses for the year ended 30 June 2026.

Note 8. Trade and other receivables (continued)

The ageing of the receivables and allowance for expected credit losses provided for above are as follows:

	Expected credit loss rate		Carrying amount		Allowance for expected credit losses	
	2026 %	2025 %	2026 $	2025 $	2026 $	2025 $
Not overdue	-	-	59,358	18,376	-	-
0 to 3 months overdue	-	-	98,881	11,750	-	-
Over 6 months overdue	100%	100%	20,240	9,531	20,240	9,531
			178,479	39,657	20,240	9,531

Movements in the allowance for expected credit losses are as follows:

	2026 $	2025 $
Opening balance	9,531	10,162
Additional provisions recognised	10,709	(631)
Closing balance	20,240	9,531

Note 9. Inventories

	2026 $	2025 $
Finished goods - at cost	71,893	199,718

Note 10. Prepayments

	2026 $	2025 $
Prepaid insurance	76,813	66,489
Other prepayments	555,838	121,828
	632,651	188,317

Note 11. Monies held in trust

	2026 $	2025 $
Pactum Medical LLC	327,517	137,099

The company has an arrangement with its US provider of outsourced logistics services, Pactum, whereby Pactum manages ReNerve's US accounts receivables (including collecting receipts from the US health service providers that are ReNerve's major customers) and makes commission payments to sales distributors. ReNerve made an initial advance of funds to Pactum to cover Pactum's logistics fees, commission payments and other working capital commitments. The monies held in trust represent that initial advance, adjusted for subsequent accounts receivable collections, commission payments, logistics fees and reimbursements to ReNerve. The company ultimately bears credit risk with the underlying health service providers.

Note 12. Plant and equipment

	2026 $	2025 $
Leasehold improvements - at cost	140,972	140,972
Less: Accumulated depreciation	(140,972)	(140,972)
	-	-
Plant and equipment - at cost	128,438	64,498
Less: Accumulated depreciation	(24,353)	(10,459)
	104,085	54,039
Computer equipment - at cost	29,230	19,498
Less: Accumulated depreciation	(19,351)	(13,724)
	9,879	5,774
	113,964	59,813

Reconciliations

Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:

	Leasehold Improvements $	Plant and Equipment $	Computer Equipment $	Total $
Balance at 1 July 2024	12,883	11,320	5,078	29,281
Additions	-	46,371	5,387	51,758
Depreciation expense	(12,883)	(3,652)	(4,691)	(21,226)
Balance at 30 June 2025	-	54,039	5,774	59,813
Additions	-	63,939	9,732	73,671
Depreciation expense	-	(13,893)	(5,627)	(19,520)
Balance at 30 June 2026	-	104,085	9,879	113,964

Note 13. Right-of-use assets

	2026 $	2025 $
Land and buildings - right-of-use	195,215	-
Less: Accumulated depreciation	(79,745)	-
	115,470	-

The company leases a commercial premises under a lease agreement originally dated 15 September 2019. During the period, the company exercised a renewal option, extending the lease for a further two years commencing 15 September 2025.

The right-of-use asset is depreciated for a period of 2 years (1 year and 2 months remaining at reporting date) and the lease liability is measured at the present value of the lease payments unpaid at the commencement date, discounted using the company's incremental borrowing rate of 3.60%. The lease agreement also provides the company with further extension options of three years and five years respectively.

Note 13. Right-of-use assets (continued)

Reconciliations
Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:

	Land and buildings $
Balance at 1 July 2024	-
Balance at 30 June 2025	-
Additions	195,215
Depreciation expense	(79,745)
Balance at 30 June 2026	115,470

Note 14. Intangibles

	2026 $	2025 $
Patents and trademarks	106,804	33,094
Less: Accumulated amortisation	(23,334)	(12,381)
	83,470	20,713

Reconciliations
Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:

	Patents and trademarks $
Balance at 1 July 2024	6,978
Additions	17,916
Amortisation expense	(4,181)
Balance at 30 June 2025	20,713
Additions	73,710
Amortisation expense	(10,953)
Balance at 30 June 2026	83,470

Note 15. Trade and other payables

	2026 $	2025 $
Trade payables	258,426	410,125
PAYG withholding	26,792	24,878
	285,218	435,003

Refer to note 22 for further information on financial instruments.

Note 16. Borrowings

	2026 $	2025 $
Premium funding facility	86,741	-
Less: unexpired interest	(2,413)	-
Total borrowings	84,328	-

The company entered into a premium funding arrangement during the year to finance annual insurance premiums. The facility is unsecured and repayable within 12 months.

Refer to note 22 for further information on financial instruments.

Note 17. Lease liabilities

	2026 $	2025 $
Current liabilities		
Office lease	100,081	-
Non-current liabilities		
Office lease	17,145	-
Total lease liabilities	117,226	-

Note 18. Employee benefits

	2026 $	2025 $
Current liabilities		
Employee benefits – Annual leave	234,580	216,887
Employee benefits – Long service leave	68,028	40,721
Employee benefits – Cash bonuses	22,400	17,500
	325,008	275,108
Non-current liabilities		
Employee benefits – Long service leave	8,115	36,812

As at 30 June 2026 amounts of $191,396 for annual leave, $68,028 for long service leave liabilities and $16,800 for cash bonuses were owed to key management personnel (2025: amounts of $175,107, $74,106 and $10,000).

Note 19. Provisions

	2026 $	2025 $
Manufacturing Liabilities	364,166	143,467

Manufacturing Liabilities
The company is party to a supply arrangement which may give rise to certain payment obligations if minimum activity levels are not met. A provision has been recognised to reflect the estimated costs that may be incurred under the terms of this arrangement.

Note 19. Provisions (continued)

Movements in provisions
Movements in each class of provision during the current financial year, other than employee benefits, are set out below:

2026	Manufacturing liabilities $
Carrying amount at the start of the year	143,467
Additional provisions recognised	220,699
Carrying amount at the end of the year	364,166

Note 20. Issued capital

	2026 Shares	2025 Shares	2026 $	2025 $
Ordinary shares - fully paid	172,300,135	142,504,018	19,384,123	17,022,293

Movements in ordinary share capital

Details	Date	Shares	Issue price	$
Balance	30 June 2024	95,130,234	$0.00	8,076,928
Share based payment	1 July 2024	572,725	$0.20	114,545
Share based payment	29 August 2024	150,000	$0.20	30,000
Initial public offering (IPO)	26 November 2024	35,000,000	$0.20	7,000,000
Conversion of convertible notes into equity	26 November 2024	10,984,847	$0.20	2,196,969
Costs of capital raising	26 November 2024	-	$0.00	(634,110)
Share based payment	14 March 2025	666,212	$0.15	99,184
Exercise of advisor options	25 March 2025	-	$0.00	138,777
Movement		142,504,018		17,022,293
Share based payment	14 July 2025	773,260	$0.11	83,054
Share based payment	17 September 2025	600,000	$0.10	60,000
Tranche 1 of capital raising	1 December 2025	21,581,591	$0.12	2,589,791
Costs of capital raising		-	$0.00	(277,977)
Tranche 2 of capital raising	15 January 2026	5,085,076	$0.12	610,209
Allocation of capital raising proceeds to attaching options	15 January 2026	-	$0.00	(764,404)
Allocation of capital raising proceeds to lead manager options	15 January 2026	-	$0.00	(128,374)
Share based payment	18 February 2026	746,089	$0.12	89,531
Share based payment	24 March 2026	1,010,101	$0.10	100,000
Movement - 30 June 2026		29,796,117		2,361,830
Balance - 30 June 2026		172,300,135		19,384,123

Note 20. Issued capital (continued)

In July 2025, the company issued 300,000 shares in lieu of cash payment to four Scientific Advisory Board members, as part payment for their services and consultancy activities. In addition, per the sales agent and market development agreement with Emerging Surgical in May 2025, the company issued 473,260 shares on 14 July 2025.

In September 2025, the company issued 600,000 shares in lieu of cash payment to Spark Plus, as part payment for their services and consultancy activities.

In December 2025, the company completed a two-tranche share placement at an issue price of $0.12 per share, raising $3.2 million in total. A total of 21,581,591 shares were issued on 1 December 2025, with a further 5,085,076 shares issued on 15 January 2026. The placement was undertaken to support accelerated sales and marketing activities, product launches, and overall growth initiatives.

In connection with the placement, the company issued 26,666,667 unlisted 1:1 attaching options and 4,000,000 unlisted lead manager options. The attaching options are exercisable at $0.18 and expire on 15 January 2028. The lead manager options are exercisable at $0.24 and expire on 15 January 2029. A portion of the placement proceeds was allocated to the options reserve based on the relative fair values of the shares and options issued.

Total capital raising costs of $1,107,755 were incurred during the year.

In February 2026, the company issued a further 425,000 shares in lieu of cash payment to four Scientific Advisory Board members, as part payment for their services and consultancy activities. In addition, the company also issued 83,333 shares to a clinical advisor and 237,756 shares to an innovation advisor as consideration for advisory services provided during the year.

In March 2026, the company issued 1,010,101 shares to Spark Plus in lieu of cash payment for investor relations and corporate advisory services.

Ordinary shares
Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the company does not have a limited amount of authorised capital.

On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

Share buy-back
There is no current on-market share buy-back.

Note 21. Reserves

	2026 $	2025 $
Options reserve	1,505,084	362,730

Options reserve
The reserve is used to recognise the value of equity benefits provided to employees and other parties as part of their remuneration and compensation for services. The reserve also includes amounts allocated from capital raising proceeds in respect of options issued as part of equity financing arrangements.

Note 21. Reserves (continued)

Movements in reserves
Movements in each class of reserve during the current and previous financial year are set out below:

	Options reserve $
Balance at 1 July 2024	202,703
Options issued during the year	298,804
Expiry of advisor options	(138,777)
Balance at 30 June 2025	362,730
Share-based payments	298,775
Expiry of options	(49,199)
Capital raising options issued	892,778
Balance at 30 June 2026	1,505,084

Note 22. Financial instruments

The company's material financial instruments include cash and cash equivalents, trade and other payables, borrowings and lease liabilities.

Financial risk management objectives

The company's activities expose it to a variety of financial risks with the only significant risk it is exposed to being liquidity risk. The company's overall risk management program focuses on the unpredictability of financial markets and seeks to minimise potential adverse effect on the financial performance of the entity. The company does not consider its exposure to interest rate risk, price risk or credit risk to be material.

Risk management is carried out by the Board of Directors who are responsible for monitoring and managing financial risk exposures.

Liquidity risk
Vigilant liquidity risk management requires the company to maintain sufficient liquid assets (mainly cash and cash equivalents) and available borrowing facilities to be able to pay debts as and when they become due and payable.

The company manages liquidity risk by maintaining adequate cash reserves and available borrowing facilities by continuously monitoring actual and forecast cash flows and matching the maturity profiles of financial assets and liabilities.

Remaining contractual maturities
The following tables detail the company's remaining contractual maturity for its financial instrument liabilities. The tables have been drawn up based on the undiscounted cash flows of financial liabilities based on the earliest date on which the financial liabilities are required to be paid. The tables include both interest and principal cash flows disclosed as remaining contractual maturities and therefore these totals may differ from their carrying amount in the statement of financial position.

2026	Weighted average interest rate %	1 year or less $	Between 1 and 2 years $	Between 2 and 5 years $	Over 5 years $	Remaining contractual maturities $
Non-derivatives						
Non-interest bearing						
Trade payables	-	285,218	-	-	-	285,218
Interest-bearing - fixed rate						
Lease liabilities	-	100,081	17,145	-	-	117,226
Borrowings	-	84,328	-	-	-	84,328
Total non-derivatives		469,627	17,145	-	-	486,772

Note 22. Financial instruments (continued)

2025	Weighted average interest rate %	1 year or less $	Between 1 and 2 years $	Between 2 and 5 years $	Over 5 years $	Remaining contractual maturities $
Non-derivatives						
Non-interest bearing						
Trade payables	-	435,664	-	-	-	435,664
Total non-derivatives		435,664	-	-	-	435,664

The cash flows in the maturity analysis above are not expected to occur significantly earlier than contractually disclosed above.

Note 23. Key management personnel disclosures

Maja McGuire
Paul Savage
Reginald Stephen Cooper
Michael Panaccio
Julian Chick
David Rhodes

Compensation
The aggregate compensation made to directors and other members of key management personnel of the company is set out below:

	2026 $	2025 $
Short-term employee benefits	752,890	637,580
Post-employment benefits	71,358	65,531
Long-term benefits	10,568	9,614
Share-based payments	244,631	-
	1,079,447	712,725

Note 24. Remuneration of auditors

During the financial year the following fees were paid or payable for services provided by William Buck, the auditor of the company, and PKF Melbourne:

	2026 $	2025 $
Audit services - William Buck		
Audit or review of the financial statements	53,468	51,863
Audit services - PKF Melbourne		
Independent Limited Assurance Report for Initial Public Offering	-	104,500

Note 25. Contingent liabilities

The company, which holds an office space lease with a $44,165 security deposit, acknowledges a contingent liability for potential deposit repayment. Management believes that the probability of occurrence is remote and, consequently, no provision has been recorded. The company will monitor this situation for future updates.

Note 26. Parent entity information

Set out below is the supplementary information about the parent entity.

Statement of profit or loss and other comprehensive income

	Parent	
	2026 $	2025 $
Loss after income tax	(5,572,439)	(3,733,918)
Total comprehensive loss	(5,572,439)	(3,733,918)

Note 26. Parent entity information (continued)

Statement of financial position

	Parent	
	2026	**2025**
	$	**$**
Total current assets	4,165,543	6,069,482
Total assets	4,545,333	6,194,173
Total current liabilities	1,343,827	962,059
Total liabilities	1,369,087	998,871
Equity		
Issued capital	19,384,123	17,022,293
Options reserve	1,505,084	362,730
Accumulated losses	(17,712,961)	(12,189,721)
Total equity	3,176,246	5,195,302

Guarantees entered into by the parent entity in relation to the debts of its subsidiaries
The parent entity had no guarantees in relation to the debts of its subsidiaries as at 30 June 2026.

Contingent liabilities
The parent entity's contingent liabilities are consistent with those disclosed in note 25.

Material accounting policy information
The accounting policies of the parent entity are consistent with those of the company, as disclosed in note 1, except for the following:

- Investments in subsidiaries are accounted for at cost, less any impairment, in the parent entity.
- Investments in associates are accounted for at cost, less any impairment, in the parent entity.
- Dividends received from subsidiaries are recognised as other income by the parent entity and its receipt may be an indicator of an impairment of the investment.

Note 27. Events after the reporting period

Non-adjusting Events:

On 9 July 2026, the company announced that it had entered into a funding facility with RiverFort Global Opportunities PCC Ltd for up to $5 million over a three-year availability period. The facility provides the company with access to staged funding to support ongoing commercialisation activities, working capital requirements and general corporate purposes.

An initial drawdown with a face value of approximately $1.6 million was completed under the facility. The drawdown provided approximately $1.361 million in net cash proceeds to the company after the initial issue discount, drawdown fee and legal costs.

The facility is intended to provide additional financial flexibility to support working capital requirements, commercialisation activities, ongoing product development and expansion into new markets. The facility is secured against future eligible R&D Tax Incentive rebates and may be drawn progressively over the three-year availability period.

In August 2026, the company issued 976,301 shares in lieu of cash payment to seven Scientific Advisory Board members, as part payment for their services and consultancy activities.

The company also obtained regulatory approval for the NervAlign® Nerve Cuff in India, Indonesia and the Philippines, expanding its regulatory footprint across the Asia-Pacific region.

Note 27. Events after the reporting period (continued)

No other matter or circumstance has arisen since 30 June 2026 that has significantly affected, or may significantly affect the company's operations, the results of those operations, or the company's state of affairs in future financial years.

Note 28. Share-based payments

A share option plan has been established by ReNerve Limited, whereby the company may, at the discretion of the Board of Directors, grant options over ordinary shares in the company to certain personnel of ReNerve Limited. Share options are issued at nil consideration.

In addition, options may also be issued to advisers of the company, for example to assist with capital raising activities.

On 24 October 2025, the company granted 870,000 options to employees under the Employee Share Option Plan (ESOP). A further 5,708,526 options, subject to the same terms and conditions, were granted on 2 December 2025. The exercise prices of the options range from $0.20 to $0.60.

On 15 January 2026, the company issued 26,666,667 unlisted 1:1 attaching options and 4,000,000 unlisted lead manager options. The attaching options are exercisable at $0.18 and expire on 15 January 2028. The lead manager options are exercisable at $0.24 and expire on 15 January 2029. A portion of the placement proceeds was allocated to the options reserve based on the relative fair values of the shares and options issued. The amount recognised in respect of these options was recorded directly in equity as part of the capital raising and was not recognised as a share-based payment expense in profit or loss.

Set out below are summaries of options granted:

Note 28. Share-based payments (continued)

2026

Grant Date	Expiry Date	Exercise price	Fair Value at grant date	Balance at the start of the year	Granted	Exercised	Expired / forfeited / other	Balance at the end of the year
15/06/2023	15/06/2026	$0.35	$0.106	250,000	-	-	(250,000)	-
15/06/2023	15/06/2026	$0.50	$0.091	250,000	-	-	(250,000)	-
17/04/2023	17/04/2028	$0.25	$0.147	60,000	-	-	-	60,000
17/04/2023	17/04/2028	$0.25	$0.147	40,000	-	-	-	40,000
01/07/2024	01/07/2029	$0.35	$0.138	50,000	-	-	-	50,000
01/07/2024	01/07/2029	$0.35	$0.138	50,000	-	-	-	50,000
01/07/2024	01/07/2029	$0.35	$0.138	50,000	-	-	-	50,000
11/09/2024	11/09/2029	$0.35	$0.137	200,000	-	-	-	200,000
11/09/2024	11/09/2029	$0.35	$0.137	200,000	-	-	-	200,000
11/09/2024	11/09/2029	$0.35	$0.137	200,000	-	-	-	200,000
22/11/2024	22/11/2027	$0.30	$0.085	2,951,595	-	-	-	2,951,595
30/04/2025	01/02/2030	$0.12	$0.060	100,000	-	-	(66,666)	33,334
30/04/2025	01/02/2030	$0.15	$0.056	100,000	-	-	(66,667)	33,333
30/04/2025	01/02/2030	$0.20	$0.050	100,000	-	-	(66,666)	33,334
30/04/2025	01/02/2030	$0.30	$0.041	100,000	-	-	(66,667)	33,333
24/10/2025	24/10/2030	$0.20	$0.056	-	123,334	-	-	123,334
24/10/2025	24/10/2030	$0.25	$0.051	-	173,333	-	(25,000)	148,333
24/10/2025	24/10/2028	$0.25	$0.033	-	150,000	-	(150,000)	-
24/10/2025	24/10/2030	$0.30	$0.047	-	273,333	-	(25,000)	248,333
24/10/2025	24/10/2028	$0.30	$0.029	-	100,000	-	(100,000)	-
24/10/2025	24/10/2028	$0.35	$0.023	-	50,000	-	(50,000)	-
02/12/2025	02/12/2030	$0.20	$0.053	-	1,613,079	-	-	1,613,079
02/12/2025	02/12/2030	$0.25	$0.048	-	100,000	-	(100,000)	-
02/12/2025	02/12/2030	$0.30	$0.044	-	100,000	-	(100,000)	-
02/12/2025	02/12/2030	$0.25	$0.048	-	538,232	-	-	538,232
02/12/2025	02/12/2030	$0.30	$0.044	-	1,944,907	-	-	1,944,907
02/12/2025	02/12/2030	$0.40	$0.038	-	640,296	-	-	640,296
02/12/2025	02/12/2030	$0.60	$0.030	-	772,012	-	-	772,012
15/01/2026	15/01/2028	$0.18	$0.029	-	26,666,667	-	-	26,666,667
15/01/2026	15/01/2029	$0.24	$0.032	-	4,000,000	-	-	4,000,000
				4,701,595	37,245,193	-	(1,316,666)	40,630,122
Weighted average exercise price				$0.31	$0.00	$0.00	$0.00	$0.22

Note 28. Share-based payments (continued)

2025

Grant Date	Expiry Date	Exercise price	Fair Value at grant date	Balance at the start of the year	Granted	Exercised	Expired / forfeited / other	Balance at the end of the year
25/03/2022	25/03/2025	$0.40	$0.097	750,000	-	-	(750,000)	-
25/03/2022	25/03/2025	$0.50	$0.088	750,000	-	-	(750,000)	-
15/06/2023	15/06/2026	$0.35	$0.106	250,000	-	-	-	250,000
15/06/2023	15/06/2026	$0.50	$0.091	250,000	-	-	-	250,000
17/04/2023	17/04/2028	$0.25	$0.147	60,000	-	-	-	60,000
17/04/2023	17/04/2028	$0.25	$0.147	40,000	-	-	-	40,000
01/07/2024	01/07/2029	$0.35	$0.138	-	50,000	-	-	50,000
01/07/2024	01/07/2029	$0.35	$0.138	-	50,000	-	-	50,000
01/07/2024	01/07/2029	$0.35	$0.138	-	50,000	-	-	50,000
11/09/2024	11/09/2029	$0.35	$0.137	-	200,000	-	-	200,000
11/09/2024	11/09/2029	$0.35	$0.137	-	200,000	-	-	200,000
11/09/2024	11/09/2029	$0.35	$0.137	-	200,000	-	-	200,000
22/11/2024	22/11/2027	$0.30	$0.085	-	2,951,595	-	-	2,951,595
30/04/2025	01/02/2030	$0.12	$0.060	-	100,000	-	-	100,000
30/04/2025	01/02/2030	$0.15	$0.056	-	100,000	-	-	100,000
30/04/2025	01/02/2030	$0.20	$0.050	-	100,000	-	-	100,000
30/04/2025	01/02/2030	$0.30	$0.041	-	100,000	-	-	100,000
				2,100,000	4,101,595	-	(1,500,000)	4,701,595
Weighted average exercise price				$0.43	$0.00	$0.00	$0.00	$0.31

Note 28. Share-based payments (continued)

Set out below are the options exercisable at the end of the financial year:

Grant date	Expiry date	2026 Number	2025 Number
15/06/2023	15/06/2026	-	250,000
15/06/2023	15/06/2026	-	250,000
17/04/2023	17/04/2028	60,000	60,000
17/04/2023	17/04/2028	40,000	40,000
01/07/2024	01/07/2029	50,000	50,000
01/07/2024	01/07/2029	50,000	50,000
01/07/2024	01/07/2029	50,000	50,000
11/09/2024	11/09/2029	200,000	200,000
11/09/2024	11/09/2029	200,000	200,000
11/09/2024	11/09/2029	200,000	200,000
22/11/2024	22/11/2027	2,951,595	2,951,595
30/04/2025	01/02/2030	33,334	100,000
30/04/2025	01/02/2030	33,333	100,000
30/04/2025	01/02/2030	33,334	100,000
30/04/2025	01/02/2030	33,333	100,000
24/10/2025	24/10/2030	123,334	-
24/10/2025	24/10/2030	148,333	-
24/10/2025	24/10/2030	248,333	-
02/12/2025	02/12/2030	1,613,079	-
02/12/2025	02/12/2030	538,232	-
02/12/2025	02/12/2030	1,944,907	-
02/12/2025	02/12/2030	640,296	-
02/12/2025	02/12/2030	772,012	-
15/01/2026	15/01/2028	26,666,667	-
15/01/2026	15/01/2029	4,000,000	-
		40,630,122	4,701,595

For the options granted during the current financial year, the valuation model inputs used to determine the fair value at the grant date, are as follows:

Grant date	Expiry date	Share price at grant date	Exercise price	Expected volatility	Dividend yield	Risk-free interest rate	Fair value at grant date
24/10/2025	24/10/2030	$0.11	$0.20	75.00%	-	4.16%	$0.056
24/10/2025	24/10/2030	$0.11	$0.25	75.00%	-	4.16%	$0.051
24/10/2025	24/10/2030	$0.11	$0.25	75.00%	-	3.37%	$0.033
24/10/2025	24/10/2030	$0.11	$0.30	75.00%	-	3.37%	$0.047
24/10/2025	24/10/2030	$0.11	$0.30	75.00%	-	3.37%	$0.029
24/10/2025	24/10/2030	$0.11	$0.35	75.00%	-	3.37%	$0.023
02/12/2025	02/12/2030	$0.11	$0.20	75.00%	-	3.93%	$0.053
02/12/2025	02/12/2030	$0.11	$0.25	75.00%	-	3.93%	$0.048
02/12/2025	02/12/2030	$0.11	$0.30	75.00%	-	3.93%	$0.044
02/12/2025	02/12/2030	$0.11	$0.25	75.00%	-	3.93%	$0.048
02/12/2025	02/12/2030	$0.11	$0.30	75.00%	-	3.93%	$0.044
02/12/2025	02/12/2030	$0.11	$0.40	75.00%	-	3.93%	$0.038
02/12/2025	02/12/2030	$0.11	$0.60	75.00%	-	3.93%	$0.030
15/01/2026	15/01/2028	$0.11	$0.18	75.00%	-	3.93%	$0.029
15/01/2026	15/01/2029	$0.11	$0.24	75.00%	-	3.93%	$0.032

Note 29. Reconciliation of loss after income tax to net cash used in operating activities

	2026 $	2025 $
Loss after income tax expense for the year	(5,572,439)	(3,733,918)
Adjustments for:		
Depreciation and amortisation	110,218	46,116
Share based payment	631,359	544,848
Interest expenses	-	249,456
Doubtful debts	-	632
Foreign exchange and cash revaluation movements	82,262	-
Borrowing expense	164,829	-
	988,668	841,052
Change in operating assets and liabilities:		
Decrease/(increase) in trade and other receivables	(855,307)	(346,121)
Decrease/(increase) in other current assets	(190,418)	(56,750)
Increase/(decrease) in trade and other payables	(149,785)	266,537
Increase/(decrease) in employee benefits	21,203	36,626
Increase/(decrease) in accrued expenses	65,374	64,238
Decrease/(increase) in other inventories	127,825	(21,720)
Increase/(decrease) in provisions	220,699	143,467
Decrease/(increase) in prepayments	(444,333)	(177,358)
Decrease/(increase) in other deposits	(11,550)	-
Net cash used in operating activities	(5,800,063)	(2,983,947)

Note 30. Related party transactions

Key management personnel
Disclosures relating to key management personnel are set out in note 23 and the remuneration report included in the directors' report.

Receivable from and payable to related parties
At 30 June 2026, the company had a receivable of $12,539 from the Chief Executive Officer relating to superannuation contributions paid in excess of contractual entitlements. The balance is expected to be recovered during the year ending 30 June 2027.

With the exception of the liabilities disclosed in note 18, there were no trade receivables from or trade payables to related parties at the current and previous reporting date.

Terms and conditions
All transactions were made on normal commercial terms and conditions and at market rates.

Note 31. Earnings per share

	2026 $	2025 $
Loss after income tax attributable to the owners of ReNerve Limited	(5,572,439)	(3,733,918)

Note 31. Earnings per share (continued)

	Number	Number
Weighted average number of ordinary shares used in calculating basic earnings per share	159,047,378	123,236,809
Adjustments for calculation of diluted earnings per share:		
Options over ordinary shares	-	100,000
Weighted average number of ordinary shares used in calculating diluted earnings per share	159,047,378	123,336,809
	Cents	**Cents**
Basic earnings per share	(3.50)	(3.03)
Diluted earnings per share	(3.50)	(3.03)

ReNerve Limited
Consolidated entity disclosure statement
As at 30 June 2026

Entity name	Entity type	Place formed / Country of incorporation	Ownership interest %	Tax residency
ReNerve Ltd	Body corporate	Australia	-	Australia
ReNerve Asia Pte. Ltd.	Body corporate	Singapore	100.00%	Singapore

ReNerve Limited
Directors' declaration
30 June 2026

In the directors' opinion:

- the attached financial statements and notes comply with the Corporations Act 2001, the Accounting Standards, the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- the attached financial statements and notes comply with IFRS Accounting Standards as issued by the International Accounting Standards Board as described in note 1 to the financial statements;
- the attached financial statements and notes give a true and fair view of the company's financial position as at 30 June 2026 and of its performance for the financial year ended on that date;
- there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable; and
- the information disclosed in the attached consolidated entity disclosure statement is true and correct.

The directors have been given the declarations required by section 295A of the Corporations Act 2001.

Signed in accordance with a resolution of directors made pursuant to section 295(5)(a) of the Corporations Act 2001.

On behalf of the directors



Maja McGuire
Independent Chair & Non-Executive Director

28 August 2026

William Buck
ACCOUNTANTS & ADVISORS

Independent auditor's report to the members of ReNerve Limited

Report on the audit of the financial report

Opinion

In our opinion, the accompanying financial report of ReNerve Limited (the Company) and its subsidiaries (the Group) is in accordance with the *Corporations Act 2001*, including:

- giving a true and fair view of the Group's financial position as at 30 June 2026 and of its financial performance for the year then ended; and
- complying with Australian Accounting Standards and the *Corporations Regulations 2001*.

What was audited?

We have audited the financial report of the Group, which comprises:

- the consolidated statement of financial position as at 30 June 2026,
- the consolidated statement of profit or loss and other comprehensive income for the year then ended,
- the consolidated statement of changes in equity for the year then ended,
- the consolidated statement of cash flows for the year then ended,
- notes to the financial statements, including material accounting policy information,
- the consolidated entity disclosure statement, and
- the directors' declaration.

Basis for opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Report* section of our report. We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* issued by the Accounting Professional & Ethical Standards Board Limited (the Code) that are relevant to audits of the financial report of public interest entities in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key audit matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial report of the current period. These matters were addressed in the context of our audit of the financial report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

	Area of focus (refer also to notes 2 and 28)	How our audit addressed the key audit matter
Going Concern	The financial statements have been prepared on a going concern basis for 30 June 2026 as outlined in note 2. The Group reports a loss of $5,572,439, net cash outflows from operating activities of $5,800,063, a net current asset position of $2,832,887 and accumulated losses of $17,712,961. During the year the Group has undertaken a capital raise of $3,200,000. $2,589,791 was received during the December quarter, with the remaining $610,209 received following shareholder approval and settlement in January 2026. Subsequent to the year end, the Group entered into a funding facility for up to $5,000,000 over a three-year availability period. An initial drawdown of $1,360,956 has been completed after the initial issue discount, drawdown fee and legal costs. We considered going concern to be a key audit matter due to the significant judgement required by management involved in assessing the Group's ability to continue as a going concern. This assessment was particularly dependent on forecast future cash flows and the successful implementation of managements planned operating and financial strategies. Based on the audit evidence obtained, we concluded that a material uncertainty related to going concern does not exist.	Our audit procedures included: — Evaluating managements forecasting accuracy by comparing prior period forecasts with actual results — Obtaining managements evaluation of the Group's ability to continue as a going concern; — Obtaining a copy of the boards financial year forecast that supports the going concern assumption, and assessing the cash flows for at least 12 months from the signing date of this report; — Assess the reasonableness of the key assumptions built into the forecast and performing sensitivity analysis on management's assumptions; — Assessing the reasonableness of disclosures made in the financial statements, and; — Inspecting relevant ASX announcements during the year relating to the capital raise and verifying cash raised to supporting documentation and bank statements.

Carrying value of R&D receivable	**Area of focus (refer also to notes 2 and 9)**
	
	Under the research and development (R&D) tax incentive scheme, the refundable R&D tax offset is 43.5%.
	
	A registration of R&D Activities Application is filed with AusIndustry in the following financial year and based on this filing, the Group receives the incentive in cash.
	
	Management performed a detailed review of the Group's total R&D expenditure to determine the potential claim under the R&D tax incentive legislation. For the year ended 30 June 2026, the R&D amount claimed is $1,033,627. The actual R&D application was submitted after audited figures in prior year which has been reflected in the current year statement of profit and loss statement. This is considered a change in estimation.
	
	The process of calculating the R&D tax rebate and receivable balance requires judgement and specialised knowledge in identifying eligible expenditure, which gives rise to anticipated R&D tax incentives. Balances in relation to R&D tax incentives are therefore considered to be a key audit matter.
		How our audit addressed the key audit matter
		
		Our audit procedures included:
		
		— Obtaining the 30 June 2026 R&D rebate calculations prepared by management and performing the following procedures:
		  — Assessing the qualifications of managements expert engaged to perform calculations;
		  — Developing an understanding of the model including identifying and assessing the key assumptions used in the calculation;
		  — Testing included testing expenditure for reasonableness against the eligibility criteria;
		  — Testing the mathematical accuracy of the balance by recalculating the R&D tax incentive calculation; and
		— Comparing the estimates made in previous years to the amount of cash received after lodgement of the R&D tax claim;
		— Evaluating the disclosures in the financial report for appropriateness and consistency with accounting standards

Other information

The directors are responsible for the other information. The other information comprises the information included in the Group's annual report for the year ended 30 June 2026, but does not include the financial report and our auditor's report thereon.

Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the directors for the financial report

The directors of the Company are responsible for the preparation of:

- the financial report (other than the consolidated entity disclosure statement) that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001*; and
- the consolidated entity disclosure statement that is true and correct in accordance with the *Corporations Act 2001,* and

for such internal control as the directors determine is necessary to enable the preparation of:

- the financial report (other than the consolidated entity disclosure statement) that gives a true and fair view and is free from material misstatement, whether due to fraud or error; and
- the consolidated entity disclosure statement that is true and correct and is free of misstatement, whether due to fraud or error.

In preparing the financial report, the directors are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

A further description of our responsibilities for the audit of the financial report is located at the Auditing and Assurance Standards Board website at:
https://www.auasb.gov.au/media/bwvjcgre/ar1_2024.pdf

This description forms part of our auditor's report.

William Buck
ACCOUNTANTS & ADVISORS

Report on the Remuneration Report

Opinion on the Remuneration Report

In our opinion, the Remuneration Report of ReNerve Limited, for the year ended 30 June 2026, complies with section 300A of the *Corporations Act 2001*.

What was audited?

We have audited the Remuneration Report included in pages 10 to 15 of the directors' report for the year ended 30 June 2026.

Responsibilities

The directors of the Company are responsible for the preparation and presentation of the Remuneration Report in accordance with section 300A of the *Corporations Act 2001*. Our responsibility is to express an opinion on the Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.

William Buck Audit (Vic) Pty Ltd
ABN 59 116 151 136

J. C. Luckins
Director
Melbourne, 28 August 2026

ReNerve Limited
Shareholder information
30 June 2026

The shareholder information set out below was applicable as at 30 June 2026.

Distribution of equitable securities
Analysis of number of equitable security holders by size of holding:

	Ordinary shares		Options over ordinary shares	
	Number of holders	% of total shares issued	Number of holders	% of total options issued
1 to 1,000	40	-	-	-
1,001 to 5,000	96	0.21	4	0.04
5,001 to 10,000	143	0.74	-	-
10,001 to 100,000	372	9.49	66	8.21
100,001 and over	203	89.56	72	91.75
	854	100.00	142	100.00
Holding less than a marketable parcel	157	-	-	-

Equity security holders

Twenty largest quoted equity security holders
The names of the twenty largest security holders of quoted equity securities are listed below:

	Ordinary shares	
	Number held	% of total shares issued
Dr Julian Chick	14,839,868	8.61
Ropehawn	12,458,090	7.23
Lucen Pty Ltd ATF The Rhodes Investment Trust	11,527,500	6.69
Mr Stephen Cooper	10,743,434	6.24
Pogginswood Pty Ltd ATF Pogginswood Super A/C	6,000,000	3.48
Alexios Adamides	3,910,000	2.27
Mr Michael Panaccio	3,662,250	2.13
Mr Stephen Paul Wirtz	3,500,000	2.03
Ruckers Investments Pty Ltd	3,400,000	1.97
Loan Group Australia Pty Ltd	3,225,000	1.87
Nicola Smith & Simon Smith ATF The Noetsie Trust	3,143,236	1.82
Dixson Trust Pty Limited	2,866,629	1.66
Rudel Pty Ltd ATF Rudel Super Fund A/C	2,461,250	1.43
Mr Peter David Koller	2,221,969	1.29
Mr Paul James Madden	2,048,296	1.19
Csiro Csiro Black Mountain Science and Innovation	2,030,000	1.18
Spark Plus Pte Ltd	1,735,100	1.01
Emerging Surgical Incorporated	1,684,922	0.98
Mariva Investments Pty Ltd ATF Mariva Property A/C	1,500,000	0.87
Escape Projects	1,480,000	0.86
	94,437,544	54.81

Unquoted equity securities

	Number on issue	Number of holders
Options over ordinary shares issued	40,630,122	142

ReNerve Limited
Shareholder information
30 June 2026

Substantial holders

Substantial holders in the company are set out below:

	Ordinary shares	
	Number held	% of total shares issued
Ropehawn Investments Pty Ltd ATF Ropehawn Super Fund A/C	12,458,090	7.23
Lucen Pty Ltd ATF The Rhodes Investment Trust	11,527,500	6.69
Zetland Road Pty Ltd ATF The Cooper (Zetland) A/C	10,170,788	5.90

Voting rights

The voting rights attached to ordinary shares are set out below:

Ordinary shares
On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

Restricted securities

Class	Expiry date	Number of shares
Escrowed shares	21 November 2026	31,255,716
Escrowed shares	21 November 2026	8,680,010
		39,935,726